Evidence based treatment of chronic stable angina

International Journal of Cardiology

Volumn 63, Issue 1, 1998, Pages 21-25

  Staniforth, Andrew D ^a  

^a QUEEN S MEDICAL CENTRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBOCYTIC AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIHYDROPYRIDINE; DIURETIC AGENT; NICORANDIL; NIFEDIPINE; NITRATE; PLACEBO; POTASSIUM CHANNEL STIMULATING AGENT;

AMBULATORY MONITORING; ANGINA PECTORIS; CARDIOVASCULAR DISEASE; CHRONIC DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; ELECTROCARDIOGRAPHY MONITORING; EVIDENCE BASED MEDICINE; HEART MUSCLE REVASCULARIZATION; HIGH RISK PATIENT; HUMAN; HYPERCHOLESTEROLEMIA; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TREATMENT OUTCOME;

EID: 0032484690     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-5273(97)00286-6     Document Type: Article

References (50)

1. [1] Shaper A, Cook D, Walker M, Macfarlane P. Prevalence of ischaemic heart disease in middle aged British men. Br Heart J 1984;51:595-605.
2. [2] Smith W, Kenicer M, Tunstall-Pedoe H, Clark E, Crombie I. Prevalence of coronary heart disease in Scotland: Scottish heart study. Br Heart J 1990;64:295-8.
3. [3] Gandhi MM, Lampe FC, Wood DA. Incidence, clinical characteristics, and short-term prognosis of angina pectoris. Br Heart J 1995;73:193-8.
4. [4] The TIDES investigators. Characteristics of a contemporary population with angina pectoris. Am J Cardiol 1994;74:226-231.
5. [5] The Swedish Angina Pectoris Aspirin Trial (SAPAT) group. Double-blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris. Lancet 1992;340:1421-1425.
6. [6] The ACIP investigators. Asymptomatic Cardiac Ischaemic Pilot (ACIP) study two year follow-up. Circ 1997;95:2037-2043.
7. [7] The RITA-2 trial participants. Coronary angioplasty versus medical therapy for angina: the second Randomised Intervention Treatment of Angina (RITA-2) trial. Lancet 1997;350:461-468.
8. [8] Scandanavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study. Lancet 1994;344:1383-1389.
9. [9] ISIS-1 Collaborative Group. Randomised trial of intravenous atenolol among 16 027 cases of suspected acute myocardial infarction. Lancet 1986;2:57-66.
10. [10] β Blocker Heart Attack Research Group. A randomized trial of propranolol in patients with acute myocardial infarction. JAMA 1982;247:1707-1713.
11. [11] The Norwegian Multicentre Study Group. Timolol induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med 1981;304:801-807.
12. [12] Beevers DG, Johnston JH, Larkin H, Davies P. Clinical evidence that beta-adrenoreceptor blockers prevent more cardiovascular complications than other antihypertensive drugs. Drugs 1993;25(S2):326-30.
13. [13] Psaty BM, Koepsell TD, Wagner EH, LoGerfo JP, Inui TS. The relative risk of incident coronary heart disease associated with recently stopping the use of β blockers. JAMA 1990;12:1653-7.
14. [14] Nidorf SM, Parsons RW, Thompson PL, Jamrozik KD, Hobbs MST. Reduced risk of death at 28 days in patients taking β blocker before admission to hospital with myocardial infarction. BMG 1990;300:71-4.
15. [15] Mangano DT, Layug EL, Wallace A, Tateo I. Effect of atenolol on mortality and cardiovascular morbidity after noncardiac surgery. N Engl J Med 1996;335:1713-20.
16. [16] The ASIST Study Group. Effects of treatment on outcome in mildly symptomatic patients with ischaemia during daily life. Circ 1994;90:762-768.
17. [17] Furberg CD, Psaty BM, Meyer JV. Nifedipine: dose related increase in mortality in patients with coronary heart disease. Circ 1995;92:1326-31.
18. [18] The TIBET study group. Total Ischaemic Burden European Trial (TIBET). Eur Heart J 1996;17:104-112.
19. [19] The Multicentre Diltiazem Postinfarction Trial Research Group. The effect of diltiazem on mortality and reinfarction after myocardial infarction. N Engl J Med 1988;319:385-392.
20. [20] The Danish Study Group on Verapamil in Myocardial Infarction. Effect of verapamil on mortality and major events after acute myocardial infarction (DAVIT-II). Am J Cardiol 1990;66:779-785.
21. [21] Rehnqvist N, Hjemdahl P, Billing E, Bjorkander I, Eriksson SV, Forslund L, Held C, Nasman P, Wallen NH. Effects of metoprolol vs verapamil in patients with stable angina pectoris - the Angina Prognosis Study In Stockholm (APSIS). Eur Heart J 1996;17:76-81.
22. [22] The GISSI investigators. GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6 week mortality and ventricular function after acute myocardial infarction. Lancet 1994;343:1115-1122.
23. [23] ISIS-4 Collaborative Group. ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58 050 patients with suspected acute myocardial infarction. Lancet 1995;345:669-685.
24. [24] Gottlieb SO, Weisfeldt ML, Ouyang P, Mellits D, Gerstenblith G. Silent ischaemia as a marker for early unfavourable outcomes in patients with unstable angina. N Engl J Med 1986;314:1214-9.
25. [25] Gottlieb SO, Gottlieb SH, Achuff SC, Baumgardner R, Mellits D, Weisfeldt ML, Gerstenblith G. Silent ischaemia on Holter monitoring predicts mortality in high risk postinfarction patients. JAMA 1988;259:1030-5.
26. [26] Gill JB, Cairns JA, Roberts RS, Costantini L, Sealey BJ, Fallen EF, Tomlinson CW, Gent M. Prognostic importance of myocardial ischaemia detected by ambulatory monitoring early after acute myocardial infarction. N Engl J Med 1996;334:65-70.
27. [27] Deedwania PC, Carbajal EV. Silent ischaemia during daily life is an independent predictor of mortality in stable angina. Circ 1990;81:748-56.
28. [28] Yeung AC, Barry J, Orav J, Bonassin E, Raby KE, Selwyn AP. Effects of asymptomatic ischaemia on long-term prognosis in chronic stable coronary disease. Circ 1991;83:1598-604.
29. [29] Rocco MB, Barry J, Campbell S, Nabel E, Cook F, Goldman L, Selwyn AP. Circadian variation of transient myocardial ischaemia in patients with coronary artery disease. Circ 1987;75:395-400.
30. [30] Mulachy D, Cunningham D, Crean P. Circadian variation of total ischaemic burden and its alteration with anti-anginal agents. Lancet 1982;2:755-9.
31. [31] The ASIS Study Group. Subsets of ambulatory myocardial ischaemia based on heart rate activity. Circ 1993;88:92-100.
32. [32] Pepine CJ. β blockers or calcium antagonists in silent ischaemia. Eur Heart J 1993;14(supp F):7-14.
33. [33] Fletcher A, McLoone P, Bulpitt C. Quality of life on angina therapy: a randomised controlled trial of transdermal glyceryl trinitrate against placebo. Lancet 1988;ii:4-8.
34. [34] Rezakovic DE, Pavicic L, Majacic M. A randomized placebo controlled, double-blind trial of transdermal nitroglycerin in stable angina pectoris. Eur Heart J 1988;9(Supp A):73-81.
35. [35] Chrysant SG, Classer SP, Bittar N, Shahidi FE, Danisa K, Ibrahim R, Watts LE, Garutti RJ, Ferraresi R, Casareto R. Efficacy and safety of extended release isosorbide mononitrate for stable effort angina pectoris. Am J Cardiol 1993;72:1249-56.
36. [36] Parker JO, Vankoughnett KA, Farrell B. Nitroglycerin lingual spray: clinical efficacy and dose-response relationship. Am J Cardiol 1986;57:1-5.
37. [37] Ryden L, Schaffrath R. Buccal verses sublingual nitroglycerin administeration in the treatment of angina pectoris: a multicentre study. Eur Heart J 1987;8:995-1001.
38. [38] Uusitalo A, Arstila M, Bae EA, Harkonen R, Keyrilainen O, Rytkonen U, Schjelderup-Mathiesen PM, Wendelin H. Metoprolol, nifedipine and the combination in stable effort angina pectoris. Am J Cardiol 1986;57:733-7.
39. [39] IMAGE Study Group. Selection of medical treatment in stable angina pectoris: results of the international multicentre angina exercise (IMAGE) study. J Am Coll Cardiol 1995;25:1516-1521.
40. [40] Brogden RN, Benfield P. Verapamil: a review of its pharmacological properties and therapeutic use in coronary artery disease. Drugs 1996;51:792-819.
41. [41] APSIS study group. Effects of metoprolol or verapamil treatment on results from exercise testing and long term electrocardiogram recordings in stable angina pectoris. Short term results of the APSIS study. Eur Heart J 1995;16 (supp):422.
42. [42] ASIS study group. Comparison of propranolol, diltiazem, and nifedipine in the treatment of ambulatory ischaemia in patients with stable angina. Differential effects on ambulatory ischaemia, exercise performance, and anginal symptoms. Circ 1990;82:1962-1972.
43. [43] Steffensen R, Grande P, Pedersen F, Haunso S. Effects of atenolol and diltiazem on exercise tolerance and ambulatory ischaemia. Int J Cardiol 1993;40:143-53.
44. [44] Findlay IN, MacLeod K, Gillen G. A double blind placebo controlled comparison of verapamil, atenolol and their combination in patients with chronic stable angina pectoris. Br Heart J 1987;57:336-43.
45. [45] Foale RA. Atenolol verses the fixed combination of atenolol and nifedipine in stable angina pectoris. Eur Heart J 1993;14:1369-74.
46. [46] The CASIS Investigators. Effect of amlodipine, atenolol and their combination on myocardial ischaemia during treadmill exercise and ambulatory monitoring. J Am Coll Cardiol 1995;25:619-625.
47. [47] The TIBET Study Group. The Total Ischaemic Burden European Trial TIBET. Effects of atenolol, nifedipine sr and their combination on the exercise test and the total ischaemic burden in 608 patients with stable angina. Eur Heart J 1996;17:96-103.
48. [48] Subramanian VB, Bowles MJ, Khurmi NS, Davies AB, Raftery EB. Randomized comparison of verapamil and nifedipine in chronic stable angina. Am J Cardiol 1982;50:696-703.
49. [49] Frishman W, Charlap S, Kimmel B, Teicher M, Cinnamon J, Allen L, Strom J. Diltiazem, nifedipine, and their combination in patients with stable angina pectoris: effects on angina, exercise tolerance and the ambulatory electrocardiographic ST segment. Circ 1988;77:774-86.
50. [50] Frampton J, Buckley MM, Fitton A. Nicorandil: a review of its pharmacology and therapeutic efficacy in angina pectoris. Drugs 1992;44:625-55.